UFP Technologies, Inc. is an American multinational developer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP Technologies manufactures a wide range of single-use medical devices, components, and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.
trading_symbol | registrant_name | time | price | change | percentage_change |
---|---|---|---|---|---|
UFPT | UFP TECHNOLOGIES INC | 2025-10-16 18:23:55 | 195 | 1.99 | 1.03 |
trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UFPT | 0000914156 | UFP TECHNOLOGIES INC | US9026731029 | 549300RJ8LY41HS70C91 | 042314970 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 100 HALE STREET | NEWBURYPORT | MA | 01950 | UNITED STATES | US | 978-352-2200 | 100 HALE STREET, NEWBURYPORT, MA, 01950 | 100 HALE STREET, NEWBURYPORT, MA, 01950 | — | — | 1963 | R. Jeffrey Bailly | 3,293 | — | 1,915,822,594 | 7,740,685 | 7,711,126 | UFP Technologies, Inc. is an American multinational developer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP Technologies manufactures a wide range of single-use medical devices, components, and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. | 2025-10-10 20:54:45 |
Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
---|---|---|---|---|---|---|
2024 | 1,915,822,594 | 531,929,770 | 38.4372 | 7,680,305 | 38,422 | 0.5028 |
2023 | 1,383,892,824 | 830,967,498 | 150.2857 | 7,641,883 | 31,832 | 0.4183 |
2022 | 552,925,326 | 158,751,151 | 40.2744 | 7,610,051 | 48,556 | 0.6421 |
Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
---|---|---|---|---|---|---|---|---|
Christopher P. Litterio | Secretary, Senior Vice President, General Counsel | 2024 | 370,000 | 0 | 303,892 | 233,276 | 32,250 | 939,418 |
Jason Holt | Chief Commercial Officer, Vice President | 2024 | 338,000 | 0 | 197,975 | 178,518 | 29,391 | 743,884 |
Ronald J. Lataille | Chief Financial Officer, Treasurer, Senior Vice President | 2024 | 460,000 | 0 | 741,416 | 354,094 | 36,786 | 1,592,296 |
Mitchell C. Rock | President | 2024 | 500,000 | 0 | 871,090 | 386,794 | 36,411 | 1,794,295 |
Christopher P. Litterio | Secretary, Senior Vice President, General Counsel | 2023 | 355,000 | 0 | 273,000 | 253,000 | 31,517 | 912,517 |
Fiscal Year | Employee Count |
---|---|
2024 | 4,146 |
2023 | 3,093 |
2022 | 2,665 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Revenue | 504,421,000 | 400,072,000 | 353,792,000 |
Cost Of Revenue | 357,728,000 | 287,847,000 | 263,532,000 |
Gross Profit | 146,693,000 | 112,225,000 | 90,260,000 |
Research And Development Expenses | 10,400,000 | 7,200,000 | 9,300,000 |
General And Administrative Expenses | 62,218,000 | 50,889,000 | 45,796,000 |
Operating Expenses | — | — | — |
Operating Income | 80,897,000 | 57,664,000 | 55,400,000 |
Net Income | 58,981,000 | 44,924,000 | 41,789,000 |
Earnings Per Share Basic | 7.69 | 5.89 | 5.52 |
Earnings Per Share Diluted | 7.58 | 5.83 | 5.45 |
Weighted Average Shares Outstanding Basic | 7,668,000 | 7,624,000 | 7,564,000 |
Weighted Average Shares Outstanding Diluted | 7,785,000 | 7,701,000 | 7,663,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Cash And Cash Equivalents | 13,450,000 | 5,263,000 | 4,451,000 |
Marketable Securities Current | — | — | — |
Accounts Receivable | 84,677,000 | 64,449,000 | 55,117,000 |
Inventories | 87,536,000 | 70,191,000 | 53,536,000 |
Non Trade Receivables | 4,979,000 | 1,297,000 | — |
Other Assets Current | 4,303,000 | 3,433,000 | 3,242,000 |
Total Assets Current | 194,945,000 | 144,633,000 | 116,346,000 |
Marketable Securities Non Current | — | — | — |
Property Plant And Equipment | 70,564,000 | 62,137,000 | 58,072,000 |
Other Assets Non Current | 447,000 | 469,000 | 3,636,000 |
Total Assets Non Current | 434,050,000 | 259,503,000 | 261,846,000 |
Total Assets | 628,995,000 | 404,136,000 | 378,192,000 |
Accounts Payable | 24,269,000 | 22,286,000 | 19,961,000 |
Deferred Revenue | 4,667,000 | 6,616,000 | 4,679,000 |
Short Term Debt | 12,500,000 | 4,000,000 | 4,000,000 |
Other Liabilities Current | 30,410,000 | 22,085,000 | 23,122,000 |
Total Liabilities Current | 76,295,000 | 58,209,000 | 55,961,000 |
Long Term Debt | 189,375,000 | 32,000,000 | 55,000,000 |
Other Liabilities Non Current | 11,144,000 | 15,181,000 | 18,220,000 |
Total Liabilities Non Current | 209,940,000 | 59,836,000 | 84,686,000 |
Total Liabilities | 286,235,000 | 118,045,000 | 140,647,000 |
Common Stock | 77,000 | 76,000 | 76,000 |
Retained Earnings | 306,501,000 | 247,520,000 | 202,596,000 |
Accumulated Other Comprehensive Income | -4,165,000 | 268,000 | -610,000 |
Total Shareholders Equity | 342,760,000 | 286,091,000 | 237,545,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Depreciation And Amortization | 8,000,000 | 7,000,000 | 7,500,000 |
Share Based Compensation Expense | 6,842,000 | 4,641,000 | 3,208,000 |
Other Non Cash Income Expense | -106,000 | -145,000 | 6,149,000 |
Change In Accounts Receivable | -1,217,000 | 9,124,000 | 16,864,000 |
Change In Inventories | 4,686,000 | 16,565,000 | 19,605,000 |
Change In Non Trade Receivables | 3,404,000 | 2,982,000 | -953,000 |
Change In Other Assets | -629,000 | -1,557,000 | 3,545,000 |
Change In Accounts Payable | -1,142,000 | 1,553,000 | 9,131,000 |
Change In Other Liabilities | -6,541,000 | 408,000 | -3,298,000 |
Cash From Operating Activities | 66,593,000 | 41,334,000 | 17,744,000 |
Purchases Of Marketable Securities | — | — | — |
Sales Of Marketable Securities | — | — | — |
Acquisition Of Property Plant And Equipment | 9,656,000 | 10,490,000 | 13,780,000 |
Acquisition Of Business | 197,477,000 | 0 | 20,653,000 |
Other Investing Activities | — | — | — |
Cash From Investing Activities | -210,164,000 | -10,488,000 | 1,291,000 |
Tax Withholding For Share Based Compensation | 4,954,000 | 2,641,000 | 1,678,000 |
Payments Of Dividends | — | — | — |
Issuance Of Common Stock | — | — | — |
Repurchase Of Common Stock | — | — | — |
Issuance Of Long Term Debt | 125,000,000 | 0 | 0 |
Repayment Of Long Term Debt | 35,125,000 | 4,000,000 | 4,000,000 |
Other Financing Activities | — | — | — |
Cash From Financing Activities | 152,393,000 | -30,024,000 | -25,894,000 |
Change In Cash | 8,187,000 | 812,000 | -6,666,000 |
Cash At End Of Period | 13,450,000 | 5,263,000 | 4,451,000 |
Income Taxes Paid | 12,829,000 | 10,568,000 | 13,200,000 |
Interest Paid | 7,893,000 | 3,537,000 | 2,721,000 |
Fiscal Year | 2024 | 2023 | 2022 |
---|---|---|---|
Earnings Per Share | 7.69 | 5.89 | 5.52 |
Price To Earnings Ratio | 31.7958 | 29.2088 | 21.3569 |
Earnings Growth Rate | 30.5603 | 6.7029 | 161.6114 |
Price Earnings To Growth Ratio | 1.0404 | 4.3576 | 0.1321 |
Book Value Per Share | 44.7001 | 37.5251 | 31.4047 |
Price To Book Ratio | 5.47 | 4.5847 | 3.7539 |
Ebitda | 87,871,000 | 66,137,000 | 65,252,000 |
Enterprise Value | 2,063,327,680 | 1,342,369,960 | 946,268,960 |
Dividend Yield | — | — | — |
Dividend Payout Ratio | — | — | — |
Debt To Equity Ratio | 0.589 | 0.1258 | 0.2484 |
Capital Expenditures | 16,427,000 | 11,065,000 | 9,003,000 |
Free Cash Flow | 50,166,000 | 30,269,000 | 8,741,000 |
Return On Equity | 0.1721 | 0.157 | 0.1759 |
One Year Beta | 1.7315 | 0.9252 | 0.6777 |
Three Year Beta | 0.9008 | 0.7718 | 0.7773 |
Five Year Beta | 0.8569 | 0.7805 | 0.7622 |
Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
---|---|---|---|---|---|
CROTEAU DANIEL C | Director | 2025-09-05 | 1,000 | D | 2,728 |
CROTEAU DANIEL C | Director | 2025-09-05 | 1,873 | D | 855 |
CROTEAU DANIEL C | Director | 2025-08-07 | 1,318 | A | 3,728 |
CROTEAU DANIEL C | Director | 2025-08-07 | 1,318 | D | 0 |
KOZIN MARC D | Director | 2025-06-04 | 625 | A | 27,310 |
Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
---|---|---|---|---|
Carnegie Investment Counsel | 2025-09-30 | 393,212 | 1,970 | 199.6 |
RICE HALL JAMES & ASSOCIATES, LLC | 2025-09-30 | 2,426,737 | 12,158 | 199.6 |
Blue Trust, Inc. | 2025-09-30 | 59,880 | 300 | 199.6 |
Avanza Fonder AB | 2025-09-30 | 181,037 | 907 | 199.5998 |
CWM, LLC | 2025-09-30 | 640,000 | 3,204 | 199.7503 |
Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
---|---|---|---|---|---|---|
TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Small Cap Fund | CFSLX | 3,749 | 787,889.84 | 0.1644 |
TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Small Cap Select Fund | CFSSX | 3,023 | 635,313.68 | 0.0442 |
AMERICAN PENSION INVESTORS TRUST | 2025-07-31 | Institutional Class | APGRX | 1,550 | 350,904.5 | 0.3794 |
AMERICAN PENSION INVESTORS TRUST | 2025-07-31 | Class A Shares | AFGGX | 1,550 | 350,904.5 | 0.3794 |
AMERICAN PENSION INVESTORS TRUST | 2025-07-31 | Class L Shares | APITX | 1,550 | 350,904.5 | 0.3794 |